The current status of checkpoint inhibitors in metastatic bladder cancer

LBA23A PHASE 1B STUDY OF PEMBROLIZUMAB (PEMBRO; MK-3475) IN PATIENTS (PTS) WITH ADVANCED UROTHELIAL TRACT CANCER

(2017) E.R. Plimack et al.   ANNALS OF ONCOLOGY

Emerging Immunotargets in Bladder Cancer

(2016) Francesco Massari et al.   CURRENT DRUG TARGETS

Systemic anti-CTLA-4 and intravesical Bacille–Calmette–Guerin therapy in non-muscle invasive bladder cancer: Is there a rationale of synergism?

(2016) Omar Fahmy et al.   MEDICAL HYPOTHESES

Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma

(2015) J. Bellmunt et al.   ANNALS OF ONCOLOGY

Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

(2015) Anne Bertrand et al.   BMC Medicine

Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor- B to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer

(2015) J. Peng et al.   CANCER RESEARCH

A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G

(2015) Edgardo D. Carosella et al.   EUROPEAN UROLOGY

Checkpoint inhibitors in bladder and renal cancers: results and perspectives

(2015) Fouad Aoun et al.   Immunotherapy

Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy

(2015) Andrew B Sharabi et al.   LANCET ONCOLOGY

Radiation in combination with immune-checkpoint inhibitors

(2015) Susan Mayor   LANCET ONCOLOGY

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inflammation and Cancer: What Can We Therapeutically Expect from Checkpoint Inhibitors?

(2015) Johannes Mischinger et al.   Current Urology Reports

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence

(2014) A. R. de Biasi et al.   CLINICAL CANCER RESEARCH

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Functional Relationship between Tumor-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer Progression

(2014) Damya Laoui et al.   Frontiers in Immunology

Incidence, survival and mortality rates of stage-specific bladder cancer in United States: A trend analysis

(2013) Firas Abdollah et al.   Cancer Epidemiology

EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines

(2013) J. Alfred Witjes et al.   EUROPEAN UROLOGY

Association between the cytotoxic T-lymphocyte antigen 4 +49A/G polymorphism and bladder cancer risk

(2013) Lei Wang et al.   TUMOR BIOLOGY

Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1

(2012) D. S. Chen et al.   CLINICAL CANCER RESEARCH

Epidemiology and Risk Factors of Urothelial Bladder Cancer

(2012) Maximilian Burger et al.   EUROPEAN UROLOGY

Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma

(2012) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

New Therapeutic Challenges in Advanced Bladder Cancer

(2012) Joaquim Bellmunt et al.   SEMINARS IN ONCOLOGY

Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression

(2012) Masayuki Inoue et al.   OncoImmunology

Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score

(2011) Georgios Gakis et al.   BJU INTERNATIONAL

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Tumor Immune Escape Mechanisms that Operate During Metastasis

(2011) D. O. Croci et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

T cell exhaustion

(2011) E John Wherry   NATURE IMMUNOLOGY

Inverse correlation of HER2 with MHC class I expression on oesophageal squamous cell carcinoma

(2010) T Maruyama et al.   BRITISH JOURNAL OF CANCER

Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial

(2010) B. C. Carthon et al.   CLINICAL CANCER RESEARCH

Genomic instability — an evolving hallmark of cancer

(2010) Simona Negrini et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Links between Innate Immunity and Normal Tissue Radiobiology

(2010) Dörthe Schaue et al.   RADIATION RESEARCH

Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients

(2009) M. Lae et al.   ANNALS OF ONCOLOGY

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways

(2008) Brian T. Fife et al.   IMMUNOLOGICAL REVIEWS

Cancer Immunology

(2008) Olivera J. Finn   NEW ENGLAND JOURNAL OF MEDICINE